|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phantom breast experience after mastectomy 显示文摘 | Lierman L M | 1988 | Oncol Nurs Forum1988，15，： | 1 |
| 2 | Double-quality control reveals high-level toxicity in gloves used for operator pro- tection in assisted reproductive technology 显示文摘 | LIERMAN S DE SUTTER P DHONT M | 2007 | Fertil Steril2007，88，4： | 1 |
| 3 | Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGERA and KIT, and against FGFR1-derived fusion kinases显示文摘 | LIERMAN E SMITS S COOLS J | 2012 | Leukemia2012，26，7： | 1 |
| 4 | FIPILl-PDGFRa D842V, a novel panresistant mutant, emerging after treatment of FIPILl-PDGFRaT6741 eosinophilic leukemia with single agent sorafenib显示文摘 | Lierman E Michaux L Beullens E | 2009 | Leukemia2009，23，5： | 1 |
| 5 | Identification of Ponatinib as a potent inhibitor of growth, migration and activation of neoplastic Eosinophils carrying FIPILI-PDGFRA 显示文摘 | Sadovnik I Lierman E Peter B | 2014 | Exp Hematol2014，42，2： | 1 |
| 6 | Effect of ionomycin on oocyte activation and embryo development in mouse 显示文摘 | Heytens E Soleimani R Lierman S | 2008 | Reprod Biomed Online2008，17，6： | 1 |
| 7 | Follicles of various maturation stages react differently to enzymatic isolation:a comparison of different isolation protocols显示文摘 | Lierman S Tilleman K Cornelissen M | 2015 | Reprod Biomed Online2015，30，2： | 1 |
| 8 | The ability of sorafenib to inhibit oncogenic PDGFRβ and FLT3 mutants and overcome resistance to other small molecule inhibitors 显示文摘 | Lierman E Lahortiga I Van Miegroet H | 2007 | Haematologica2007，92，1： | 1 |
| 9 | Sorafenib is a potent inhibitor of FIP1L1-PDGFRαand the imatinib-resistant FIPI LI PDGFRαT674I mutant显示文摘 | FOLENS C STOVER EH | 2006 | J Blood2006，108，4： | 1 |
| 10 | Double-quality control reveals high -Ievel toxicity in gloves used for operator protection in assisted reproductive technology 显示文摘 | Lierman S De Sutter P Dhont M | 2007 | Fertil Steril2007，88，4： | 1 |
| 11 | FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib 显示文摘 | Lierman E Michaux L Beullens E | 2009 | Leukemia2009，23，5： | 1 |
| 12 | The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t (7;8)(q22;p11)显示文摘 | Wasag B Lierman E Meeus P | | 0，，： | 1 |
| 13 | Developmental competence of parthenogenetic mouse and human embryos after chemical or electrical activation显示文摘 | Versieren K Heindryckx B Lierman S | | 0，，06： | 1 |
| 14 | The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8) (q22;p11)显示文摘 | Wasag B Lierman E Meeus P | 2011 | Haematologica2011，96，6： | 1 |
| 15 | The kinase inhibitor TKI258 is active against the novel CUX1 FGFR1 fusion detected in a patient with T-lymphoblastie leukemia/lymphoma and t (7; 8)(q22pll)显示文摘 | Wasag B Lierman E Meeus P | 2011 | Haematologica2011，96，6： | 1 |
| 16 | Screening of JAK2 V617F and MPL W515 K/L negative essential thrombocythae- mia patients for mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1 显示文摘 | AI Assaf C Lierman E Devos T | 2014 | Br J Haematol2014，165，5： | 1 |
| 17 | The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)显示文摘 | Wasag B Lierman E Meeus P | 2011 | Haematologica2011，96，6： | 1 |
| 18 | Ponatinib is active against imatinib resistant mutants of FIP1L1-PDGFRA and KIT, and againstFOFRl-derived fusion kinases显示文摘 | Lierman E Smits S Cools J | 2012 | Leukemia2012，26，7： | 1 |
| 19 | Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT,and against FGFR1-derived fusion kinases显示文摘 | Lierman E Smits S Cools J | 2012 | Leukemia2012，26，7： | 1 |
| 20 | The influence of early em- bryo traits on human embryonic stem cell derivation efficiency 显示文摘 | O'Leary T Heindryckx B Lierman S | 2011 | Stem Cells Dev2011，20，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员